Skip to main content
. 2024 Mar 25;6(7):101072. doi: 10.1016/j.jhepr.2024.101072

Fig. 5.

Fig. 5

RASs in patients with rare vs. common HCV GTs.

(A) NS5A RASs detected in patients after NS5Ai failure. Pos. 28 not resistant in GT3a, Pos. 30 not resistant in GT1b. The data for GT1a, GT1b and GT3a are taken from Dietz et al. J. Hepatol., 2023. (B) NS5A RASs in DAA-naive patients. (C) Frequency of Y93H after NS5Ai failure in patients with rare GTs compared with common subtypes. (D) Prevalence of S282T after sofosbuvir treatment failure in patients with rare GT in comparison to patients with common subtypes. DAA, direct-acting antiviral; GT, genotype; NS5Ai, NS5A inhibitor; RASs, resistance-associated substitutions. #In patients with NS5A sequencing data available; §in patients with NS5B sequencing data available; ∗data from Dietz et al. J. Hepatol., 2023; ∗∗data from Dietz et al. Gastroenterology, 2018.